The pharmaceutical company behind the birth control pill Tydemy is recalling two batches of the drug because of potentially reduced effectiveness.
The pharmaceutical company behind the birth control pill Tydemy is recalling two batches of the drug because they may have reduced effectiveness.that it was recalling the batches after tests showed the pills had decreased levels of ascorbic acid, an inactive ingredient, and high levels of a"known impurity."
However, Lupin and the FDA said they have “not received any reports of adverse events” related to use of the pills. Lupin’s news release advises patients taking Tydemy to continue doing so in the short term and to “immediately contact their pharmacist, physician, or medical provider for advice regarding an alternative treatment.”
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Thousands of Tydemy birth control pills recalled, may be ineffective, FDA warnsA drugmaker recalled thousands of birth control pills after testing found they might have lower effectiveness.
Weiterlesen »
FDA warns that some lots of Tydemy birth control pill may be ineffectiveThe Food and Drug Administration said Tuesday that two lots of birth-control pill Tydemy, made by privately held Lupin Pharmaceuticals, “may have reduced...
Weiterlesen »
Some Lots of Tydemy Birth Control Pills Recalled Due to 'Reduced Effectiveness'Certain lots of the prescription birth control pill Tydemy may be less effective than expected, potentially resulting in an unintended pregnancy, because the pills do not contain enough of an active ingredient.
Weiterlesen »
Thousands of birth control pills recalled, may be ineffective, FDA warnsA total of 4,179 boxes of Tydemy brand birth control pills have been recalled, which amounts to about 350,000 tablets that might be less effective at stopping pregnancy.
Weiterlesen »
FDA, DEA call on drugmakers to boost manufacturing amid ongoing shortage of prescription stimulants | CNNAmid an ongoing shortage of prescription stimulants in the US, federal agencies are calling on drugmakers to boost manufacturing and on health care providers to closely monitor prescribing practices.
Weiterlesen »